Legal & Regulation

The UK’s proposed tax reform offers clarity to secondaries buyers

The new legislation will bring buyers’ offshore execution to an end, which under stamp duty came with its own grey areas in a digital age, Hogan Lovells Cadwalader’s Elliot Weston tells Secondaries Investor.

SEC zeroes in on private funds valuations

Examiners ask about funds by name in opening requests. Enforcement has picked up the scent, too, affiliate title Private Funds CFO has learned.

The art of self-governance

There’s reasons on all sides to settle on market practice when it comes to continuation vehicle guidance – lest regulators decide it for you.

From ‘status quo’ to ‘remain in place’: ILPA updates CV guidance for an evolving market

The industry body’s prior guidance was ‘silent on a lot of things’, chief executive Jennifer Choi tells Secondaries Investor.

Fees and expenses survey: Seven key takeaways

Market participants have a keen eye on fees and expenses related to GP-led deals given many LPAs were not drafted with these transactions in mind.

Buyers and sellers pay over $25,000 for legal counsel per LP-led fund interest

GP counsel fees paid by both sides of a deal ranged from zero to around $79,000, according to research by AI workflow automation platform AltConvey.

CVs are not struck out of 401(k) plans

While the US Department of Labor’s March proposal flagged CVs as an area of concern in 401(k) plans, it should not be taken as a signal to rule them out.

Goodwin: Why innovation is core to the secondaries market

The secondaries industry has always been solutions-focused. That continues to be the case as the market expands rapidly in both breadth and depth, say Goodwin partners Ravi Chopra and Jacqui Eaves.

Where next for secondaries? Buyouts tops investor poll

The secondaries market is poised for continued growth and innovation, as well as increased regulatory scrutiny.

Six key insights from our Global Market Survey

The key takeaways from Secondaries Investor’s inaugural survey of LPs, secondaries buyers, GPs and advisers.